Coronavirus update: U.S. court upholds hospital's mandatory vaccination policy
The global tally of confirmed cases of COVID-19 climbed above 176 million on Monday, and U.K. Prime Minister Boris Johnson was expected to delay the full lifting of restrictions on movement amid a surge in new cases caused by the Delta variant.
There was positive vaccine news from Novavax Inc., which said a Phase 3 study of its COVID jab found it was 90.4% effective overall. The study involving almost 30,000 patients found the vaccine provided 100% protection against moderate and severe disease. In the U.S., a Texas hospital system’s mandatory COVID-19 vaccination policy for employees can stand after a federal judge on Saturday dismissed a closely watched lawsuit from workers refusing to get the shot.
The U.S. has now fully vaccinated 43.4% of its overall population, according to a tracker created by the Centers for Disease Control and Prevention. That means 143.9 million people have received two shots of the two-dose vaccines developed by Pfizer Inc. PFE, -1.67% and German partner BioNTech SE BNTX, -5.47% and Moderna Inc. MRNA, -5.23%, or one shot of the Johnson & Johnson JNJ, -0.44% one-shot vaccine. The AstraZeneca AZN, -0.29% AZN, +0.
However, the pace of vaccinations has continued to slow, raising doubts that President Joe Biden will reach his goal of 70% of the population vaccinated by July 4. So far, Maine, Vermont, Massachusetts, Connecticut and Rhode Island are the only states to have fully inoculated more than 50% of their populations, according to data aggregated by Johns Hopkins University.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novavax Covid vaccine shows over 90 percent efficacy, drugmaker saysCompany says study of nearly 30,000 volunteers in US and Mexico shows its vaccine protects against variants and will seek authorisation by the third quarter of 2021.
Read more »
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
Read more »
Novavax COVID-19 vaccine more than 90% effective in U.S. trialNovavax Inc (NVAX.O) on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.
Read more »
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world yet another weapon against the virus at a time when developing countries are desperate for doses. While demand for COVID-19 shots in the U.S. has dropped off dramatically and the country has more than enough doses to go around, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting supplies in poor parts of the world.
Read more »
Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.
Read more »
Novavax Reports Over 90% Efficacy For Its Covid Vaccine—Including Against VariantsThe Maryland-based company's vaccine was also found to be 100% effective at preventing moderate and severe cases of the disease.
Read more »